A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin α_vβ₃, ± dacarbazine in patients with stage IV metastatic melanoma

Abstract

The survival results in both treatment arms of this study were considered unlikely to result in clinically meaningful improvement over dacarbazine alone.